根据新指南，生活方式调整应包括保持或达到健康体重、遵循有益心脏健康的饮食方式、减少钠摄 入量、管理压力、进行适度的体育活动以及进行力量训练等抗阻运动、减少或戒掉酒精摄入等。 在饮酒方面，2017年版指南建议，如果选择喝酒，则女性每天最多喝一杯，男性每天最多喝两杯。 新指南建议尽量减少酒精摄入，理想的选择是戒酒。在饮食方面，新指南的建议没有变化，要多吃水 果、蔬菜、全谷物和低脂乳制品等，减少摄入的饱和脂肪及脂肪总量。钠的摄入量应少于每天2300毫 克，理想摄入量是每天1500毫克。对于超重或肥胖的人，新指南建议至少减掉体重的5%。对于严重肥 胖的人，新指南建议采用经临床证实的干预措施如饮食调整、运动以及减肥药等。 新指南已发表在《美国心脏病学会杂志》上。 新华社洛杉矶8月15日电 美国心脏协会和美国心脏病学会等机构日前发布一份新的高血压临床实践 指南，这是美国自2017年以来首次更新高血压指南。新指南建议针对临界高血压应尽早干预和治疗。 长期以来，心血管疾病是全球首要死因。控制血压有助于降低心血管疾病的发病和死亡风险，还可 以降低罹患肾病、2型糖尿病和阿尔茨海默病等疾病的发病率。 美国近一半的成年人血压高于正常 ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 grew 12% year over year to $82.4 million, despite a $25 million one-time milestone payment in Q2 2024, indicating strong underlying business performance [20][21] - U.S. net product revenue increased 42% year over year to $40.3 million and grew 15% sequentially [21] - Operating income from ongoing business reached approximately $15 million, marking the first quarter of operating income in the company's history [5][19] Business Line Data and Key Metrics Changes - Collaboration revenue decreased by approximately 7% to $42.1 million, impacted by a settlement agreement milestone with DSC, but grew 105% when excluding this milestone [21][22] - Research and development expenses decreased by 37% to $7.25 million, while selling, general, and administrative expenses decreased by 11% to $39.5 million [22] Market Data and Key Metrics Changes - The company reported over 650,000 visits to its consumer statin intolerance website and more than 600,000 click-throughs to its physician site during Q2 [8] - The total prescriber base increased to over 28,000 healthcare practitioners, with a 10% increase in total retail prescription equivalents [10][21] Company Strategy and Development Direction - The company is focused on expanding its cardiovascular risk reduction portfolio, including plans to develop a triple combination product [12][13] - The marketing strategy emphasizes reaching statin intolerant patients, with successful campaigns like "Can't take a statin, make NexoZet happen" driving brand awareness [7][12] - The company aims to transition to sustainable profitability starting in 2026, supported by strong operational results and global growth [19][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable profitability due to strong performance and ongoing global growth [19][25] - The endorsement of NEXLETOL and NEXLASET by leading cardiovascular professional societies is seen as a validation of the company's science and marketing efforts [7][12] - Management highlighted the importance of digital marketing and consumer engagement in driving growth and awareness [9][11] Other Important Information - The company reached settlement agreements with three generic manufacturers to delay the marketing of generic versions of Nexletol until February 2040 [13] - The company is advancing its pipeline, including a program targeting primary sclerosing cholangitis, which represents a significant market opportunity [14] Q&A Session Summary Question: What is the status of prior authorizations relative to the total addressable market for the product? - Management reported over 80% approval rates for prior authorizations, with some regions achieving even higher rates [29][30] Question: What will the working capital benefits from the transfer to DSC look like on the balance sheet? - The company expects to ramp down inventory production as DSC takes over, with inventory decreasing in the second half of the year [31][32] Question: What drove the significant growth from April to May? - The growth was attributed to the strategy targeting statin intolerant patients and increased awareness through marketing campaigns [36][37] Question: How does the company view consensus U.S. revenue for the year? - Management indicated they are tracking well ahead of consensus and expect to achieve milestone payments in the second half of the year [44][45] Question: What is the outlook for gross margin trends in the back half of the year? - Management expects benefits from the tech transfer to kick in early next year, with steady favorable gross to net ratios anticipated [51][55] Question: How will Nexletol remain competitive in the non-statin LDL space? - The company highlighted its unique position as the only product studied in statin intolerant patients and its strong patent position [60][62]

Core Viewpoint - The article emphasizes the increased cardiovascular risks during summer due to high temperatures and suggests various protective measures for heart health. Group 1: Summer Heart Risks - Cardiovascular disease-related mortality increases by 2.1% for every 1°C rise in temperature [1] - Heart attack cases surge during summer, particularly after the hottest days, due to three main pressures: temperature extremes, cold food consumption, and emotional stress [1][2][3] Group 2: Recommendations to Avoid Heart Risks - Avoid drinking ice water immediately after exercise to prevent sudden blood vessel constriction and increased blood pressure [4] - Do not blow air conditioning directly on oneself after sweating; allow the body to adjust gradually [5] - Wait 10-15 minutes after sweating before taking a cold shower to prevent blood vessel spasms [6] - Limit sugary drinks; consuming more than two servings daily increases cardiovascular disease risk by approximately 21% [7] Group 3: Heart Health Practices - Drink warm water before bed and upon waking to dilute blood and reduce clotting risk [9] - Drink small amounts of water frequently rather than large quantities at once to avoid overloading the heart [10] - Incorporate fresh fruits and vegetables into the diet to ensure adequate potassium intake and support heart health [11] - Take short naps during the day to alleviate fatigue and support heart health [12] - Engage in brisk walking for at least 30 minutes daily to lower the risk of heart disease and stroke [13]

Core Viewpoint - The successful implementation of an innovative heart surgery technique for high-risk coronary artery disease patients demonstrates advancements in medical technology and the importance of multidisciplinary approaches in healthcare [1][2]. Group 1: Medical Innovation - The Yunnan Provincial First People's Hospital successfully performed a "non-extracorporeal circulation heart bypass + vascular anastomosis black technology" surgery on a 67-year-old patient with severe coronary artery disease [1]. - This innovative technique significantly reduces the risk of vascular rupture by providing a "nano protective suit" for the blood vessels, offering new treatment options for patients previously deemed "inoperable" [2]. Group 2: Patient Recovery and Rehabilitation - Post-surgery rehabilitation is crucial, with a personalized three-phase recovery plan that includes early activity, cardiopulmonary function recovery, and lifestyle changes [2]. - The patient showed significant improvement in mobility, progressing from being unable to sit up for more than five minutes to walking for over ten minutes [2]. Group 3: Public Health Awareness - Long-term smoking increases the risk of coronary heart disease by three times, and high blood pressure accelerates vascular calcification [3]. - Preventive measures for cardiovascular diseases include smoking cessation, blood pressure control, healthy diet, and regular exercise, with a recommended blood pressure target of below 130/80 mmHg for middle-aged individuals [3].

Core Insights - Recent studies reveal additional benefits of shingles vaccination, including a potential reduction in cardiovascular disease risk by 23% among vaccinated individuals aged 50 and above [2][3] - The protective effects of the shingles vaccine are most significant within 2 to 3 years post-vaccination and can last up to 8 years [2] - Shingles is caused by the varicella-zoster virus, which can lead to severe complications, particularly in older adults and those with weakened immune systems [2][3] Group 1: Shingles Vaccine Benefits - A large-scale study involving 2.2 million individuals showed that shingles vaccination significantly lowers the risk of cardiovascular events such as stroke and heart failure [2] - The vaccine may also reduce the risk of dementia by 20% over seven years, supporting the theory that viral infections can lead to neurodegenerative diseases [4] - The shingles vaccine is associated with a reduction in chronic disease burden for patients with conditions like diabetes and chronic obstructive pulmonary disease [3] Group 2: Vaccine Efficacy and Recommendations - The currently available shingles vaccines in China include a live attenuated vaccine and a recombinant vaccine, with the latter showing over 90% efficacy in preventing shingles and postherpetic neuralgia [5] - The recombinant vaccine, Shingrix, requires two doses administered 2 to 6 months apart and is recommended for individuals aged 50 and older [5] - The live attenuated vaccine can be administered as a single dose to adults aged 40 and above [5]

Group 1 - Cardiovascular diseases are recognized as the leading health threat to residents in China, yet there are significant misconceptions among the public regarding these conditions [1] - Two major blind spots in public understanding of cardiovascular diseases include the belief that "no pain means no heart attack" and the misattribution of atypical symptoms to other diseases, which can lead to misdiagnosis [2] - There is a strong emphasis on the importance of early detection and prevention through individualized health screenings, which can more accurately assess individual health risks compared to traditional screening methods [2] Group 2 - Individualized health screenings can identify potential risk groups for high blood lipids and high blood sugar, allowing for targeted health management recommendations [2] - For individuals with elevated blood lipids or blood sugar that do not yet meet diagnostic criteria, lifestyle changes such as a balanced diet, regular exercise, and good sleep hygiene are recommended to prevent disease progression [2]